Patent: 5,545,403
✉ Email this page to a colleague
Summary for Patent: 5,545,403
| Title: | Method for treating a mammal by administering a CHO-glycosylated antibody |
| Abstract: | The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation. |
| Inventor(s): | Page; Martin J. (Beckenham, GB) |
| Assignee: | Burroughs Wellcome Co. (Research Triangle Park, NC) |
| Application Number: | 08/155,864 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,545,403
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2013-08-13 |
| Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2013-08-13 |
| Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2013-08-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,545,403
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 176926 | ⤷ Try a Trial |
| Austria | 297988 | ⤷ Try a Trial |
| Australia | 645355 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
